SREBF1 and metabolic dysfunction-associated steatotic liver disease: In 2018, Yao et al. demonstrated that in a palmitic acid (PA)-induced AML-12 murine parenchymal hepatocyte model of MASLD, SIRT1 expression is significantly downregulated, thereby impairing downstream lipid metabolic regulators such as sterol regulatory element-binding protein 1 (SREBP-1)41.